RecruitingNCT04935853
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Enrollment
1,350 participants
Start Date
May 23, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded)
- Age \> 18 years
- Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
- Written written non-opposition +/- signed informed consent for genetic studies (N.B.:
- exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol
Exclusion Criteria4
- Patient under guardianship, curatorship or legal protection
- Pregnant or breastfeeding women
- Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
- Refusal to participate in the study
Locations(32)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04935853
Related Trials
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
NCT066480571 location
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253168 locations
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Ligufalimab and Cadonilimab in Advanced Liver Cancers
NCT067898481 location